AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02160782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once daily during randomized withdrawal period
Study NCT02250859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101, Minocycline 4% foam
Description: FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
Study NCT01847001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT imaging
Description: (Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: (Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: (Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: (Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: (Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: (Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: (Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
Study NCT01847001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premedication
Description: As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-nausea therapy
Description: In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
Study NCT01847001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
Study NCT04645888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted tooth surgery
Description: Surgical extraction of İmpacted tooth
Study NCT03454685 — intervention group
Intervention type: OTHER
Intervention: without intervention type
Description: Without intervention,this study is just an observational study.
Study NCT04798495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal interdisciplinary rehabilitation programme (HAPPY)
Description: A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
Study NCT01460589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: timing to initiate the adjuvant chemotherapy
Description: Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Study NCT01460589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing to initiate the adjuvant chemotherapy
Description: Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Study NCT02828969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone call or physical consultation
Study NCT02387177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 1
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
Study NCT02387177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 2
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
Study NCT02003365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 10 mg
Description: Extended-release formulation
Study NCT02003365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 40 mg
Description: Extended-release formulation
Study NCT02003365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Immediate-release formulation
Study NCT03418623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GET73
Description: GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
Study NCT03418623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
Study NCT00694915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w
Description: Immunomodulator
Study NCT00694915 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Bacillus Calmette-Guerin)
Description: Immunotherapeutic agent
Study NCT00537238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Study NCT00537238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: 1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Study NCT01054326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Study NCT01054326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Study NCT00632073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
Study NCT00954304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 1mg
Description: HM30181AK 1mg tablet
Study NCT00954304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 5mg
Description: HM30181AK 5mg tablet
Study NCT00954304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 15mg
Description: HM30181AK 15mg tablet
Study NCT00954304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 60mg
Description: HM30181AK 60mg tablet
Study NCT00954304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses.
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
Study NCT03107182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
Study NCT02292199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS High Frequency
Description: TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
Study NCT02292199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Low Frequency
Description: TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
Study NCT03107182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Description: Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
Study NCT03107182 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant RT
Description: Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
Study NCT03107182 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).
Study NCT04030650 — intervention group
Intervention type: OTHER
Intervention: Functional analyses
Description: 2-minute walking test 200-metre walking test
Study NCT04030650 — intervention group
Intervention type: OTHER
Intervention: 3D analysis of walking and balance
Description: Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
Study NCT04030650 — intervention group
Intervention type: OTHER
Intervention: Functional analyses
Description: 400-metre walking test 200-metre walking test
Study NCT04394611 — intervention group
Intervention type: OTHER
Intervention: Obstetric ultrasound- doppler examination
Description: Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
Study NCT03802851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of Prostate (HoLEP)
Description: Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
Study NCT00214669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE (Professional Asthma Care Education)
Description: Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
Study NCT00214669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Led Expert Patient Programme
Description: Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
Study NCT00214669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma self management education by a specialist nurse
Description: asthma education and self management, asthma action plans
Study NCT02340507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and bread (high GI)
Description: Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
Study NCT02340507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and bread (low GI)
Description: Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
Study NCT03068598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn watch/Suunto Spartan Ultra watch
Description: The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
Study NCT03375827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IGCDG
Description: The IGCDG reviews topics of concern for patients with metastatic breast cancer.
Study NCT03037801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)
Description: IPV physiotherapy 3 times a day
Study NCT01938872 — intervention group
Intervention type: PROCEDURE
Intervention: paclitaxel eluting balloon angioplasty in below-the-knee lesions
Study NCT03180697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: APT MR Imaging
Description: Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pump
Description: In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pump
Description: In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: after induction of anaesthesia (T0)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: after induction of anaesthesia (T0)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: after arrival at the ICU (T1)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: after arrival at the ICU (T1)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: 4 hours in ICU (T2)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: 4 hours in ICU (T2)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: the first postoperative day (T3)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.